Highlights

  • Bausch Health reports Q4 EPS of USD 1.08, missing consensus by USD 0.14.
  • Shares climbed 3.6% to USD 6.21 despite weak profitability metrics.
  • Institutional investors hold 78.65% of BHC stock amid mixed analyst ratings.

Bausch Health Cos Inc (NYSE:BHC) released its Q4 earnings, reporting USD 1.08 per share, below the consensus estimate of USD 1.22 by USD 0.14, according to Zacks. The company recorded a net margin of 3.61%, while return on equity showed a striking negative figure of ‑9,620.34%, highlighting ongoing challenges in capital efficiency.

Despite the earnings miss, BHC shares rose 3.6% to USD 6.21 on Wednesday, with trading volume reaching 2,779,723 shares compared to the 50-day average of 2,155,968. The stock’s 52-week range remains USD 4.25–USD 8.69, with a market capitalisation of roughly USD 2.3 billion and a P/E ratio of 6.4.

Market Activity and Valuation Metrics
The company’s balance sheet reflects a current ratio of 1.30, a quick ratio of 0.97, and a debt-to-equity ratio of 57.48. Shares are trading slightly below the 50-day and 200-day moving averages of USD 6.67 and USD 6.69, respectively, while the stock’s beta stands at 0.42, suggesting lower volatility compared to the broader market.

Analyst coverage remains mixed. Wall Street Zen downgraded the stock from “strong-buy” to “buy,” while Truist Financial lifted its target from USD 7.00 to USD 8.00 with a “hold” rating. Barclays set an “equal weight” rating and USD 8.00 price objective, and Raymond James reiterated a “market perform” rating. Overall, BHC maintains an average analyst rating of “Hold” with a consensus price target of USD 8.67.

Institutional Activity Signals Interest
Bausch Health continues to attract institutional investors. Goldman Sachs Group Inc. increased its holdings by 97.1% to 948,322 shares valued at USD 6,136,000. UBS AM owns 324,847 shares, while Geode Capital Management LLC increased its position by 11.2% to 840,418 shares. Overall, institutional investors control 78.65% of the company’s stock, underscoring continued interest from large market participants.

With brokerage assessments diverging, Bausch Health is navigating a period marked by mixed performance metrics and continued institutional interest. Market participants are monitoring earnings trends and analyst guidance as the company operates under challenging profitability conditions and aims to maintain shareholder confidence.

FAQs

Q1. What are the latest brokerage ratings for Bausch Health Cos?
Ans - Several analysts rate the stock as “Hold” with a consensus price target of USD 8.67.

Q2. How did BHC perform in Q4 FY26?
Ans - The company reported EPS of USD 1.08, missing the consensus estimate by USD 0.14.

Q3. What is the institutional ownership in BHC?
Ans - Institutional investors hold approximately 78.65% of the company’s shares.